cirrhosis, hepatic failure, hepatocellular carcinoma, cardiovascular disease, and ultimately death. 2, 3 Therefore, it is important to recognize NAFLD/NASH and to treat this disease in the earliest stages.
After pancreatoduodenectomy (PD), approximately 23-37% of the patients develop NAFLD/NASH. [3] [4] [5] [6] [7] A significant number of these patients did not suffer from metabolic syndrome preoperatively. It is likely that mechanisms underlying postoperative NAFLD/NASH differ from mechanisms underlying common metabolic NAFLD/NASH.
Remarkably, hepatic steatosis following PD was related to nonobesity, lack of hyperlipidaemia or insulin resistance, indicating another cause for NAFLD/NASH than metabolic syndrome. 3, 8 Still, the process leading to the NAFLD/NASH in these postoperative patients is unclear.
Some studies suggest that malnutrition or malabsorption of essential nutrients caused by exocrine pancreatic insufficiency (EPI) leads to NAFLD/NASH. 3, 4, [6] [7] [8] [9] Changes in metabolism resulting in hepatic steatosis could lead to sensitivity for hepatocyte damage, inflammation, and fibrosis. 8, 10 Pancreatic enzyme administration as treatment of EPI has beneficial impact on hepatic steatosis after PD,
indicating that EPI could be the main cause of new onset NAFLD/ NASH in these patients. 3, 9 Other evidence for malnutrition in patients with EPI or after PD is the report of increase of taurine serum levels and decrease of methionine, tyrosine, albumin, cholinesterase, zinc, and total cholesterol serum levels. The aim of this study is to determine the incidence of new onset NAFLD/NASH and EPI after resection of pNET. Risk factors for the development of NAFLD/NASH were assessed in a large cohort with relatively long-term follow-up after resection of pNET.
| MATERIALS AND METHODS

| Study design
This is a retrospective cohort study, performed in the Academic 
| Exclusion criteria
Patients were excluded in case of age <18 year, another histopathological diagnosis than pNET after operation, operation and follow-up in another hospital than AMC, excessive alcohol use (>14 units a week for women and >21 units a week for men), diabetes mellitus, obesity (BMI >30), pre-existent fatty or other liver disease, daily use of steroids, death within 3 months after surgery.
| Analysis
Statistical analyses were performed using SPSS software, version 23 
| Patient characteristics
Of the 112 included patients, 54 were male, with a mean age of 53.9 ± 12.4 years. See Table 1 for baseline characteristics. All four patients with MEN1 syndrome underwent partial pancreatic resection.
Of these patients, two were diagnosed with multiple insulinomas, one with multiple gastrinomas and one with multiple NF-pNETs. Three of the four MEN1 patients had recurrent disease. Overall, 26 patients (23.2%) were identified with recurrent disease; 7 with loco-regional disease and 19 with distant recurrence. At diagnosis, three patients had lymph node metastases and three had liver metastases. Seven patients received chemotherapy after pancreatic surgery; one due to recurrent disease of NF-pNET in the liver after failure of other systemic treatment, one as adjuvant treatment due to initial suspicion of pancreatic adenocarcinoma until definitive pNET histopathology was determined and 5 due to other malignancies. SSA and peptide receptor radionuclide therapy (PRRT), were given to 5.4% and 3.6% of patients, respectively, in context of recurrent disease ( developed NAFLD/NASH after enucleation, this was not statistically significant (P = 0.281, Table 2 ). In contrast, four of nine patients (44.4%) after central and distal pancreatectomy (± splenectomy) developed NAFLD/NASH (P = 0.070, Table 2 ). Other types of resection, type of pNET and gender were also not statistically differing between both patient groups.
Recurrent disease was present in 10 patients (62.5%) with postoperative NAFLD/NASH (P = 0.004, Table 2 Patients with NAFLD/NASH had lower mean asparagine levels than patients without this hepatic steatosis (35.8 vs 46.9 μmol/L; P = 0.056, Table 3 ). Other laboratory values were not different between the two patient groups (Table 3) .
| Factors associated with postoperative EPI
As shown in Table 4 , postoperative EPI was detected in 51 patients (49.0%). All 49 patients using pancreatic enzymes were suffering from EPI, according to our definitions. Thirty-nine patients used the enzymes on a daily basis and one to a varying extent with a minimum of several days a week. The other nine patients used the supplements sporadically or stopped treatment completely due to side effects, noncompliance or inadequate treatment effect.
Whereas the majority of NF-pNET patients developed postoperative EPI (82.4% vs 62.3%, P = 0.029), the majority of insulinoma patients did not (5.9% vs 34.0%, P < 0.001, Table 4 ). After PD, 30 of 39 patients (76.9%) suffered from EPI (P < 0.001). These patients developed EPI more often than patients who underwent enucleation and other types of pancreatic resection (OR 7.0, 95% CI 2.8-17.3, P < 0.001).
Multivariate analysis showed that PD was the sole independent risk factor associated with EPI (P = 0.012) and that diagnosis of insulinoma was the sole independent protective factor against EPI (P = 0.037, Table 5 ).
Because supplementation of pancreatic enzymes is a postoperative consequence, this variable was excluded from multivariate analysis. were not statistically significant (P = 0.145 and P = 0.063, respectively).
Only in 2 of 16 patients (12.5%) new onset NAFLD/NASH was diagnosed during follow-up, but were not prescribed treatment or Other amino acids are taurine, aspartic acid, hydroxyproline, threonine, serine, asparagine, glutamic acid, glutamine, proline, glycine, alanine, citrulline, 2-aminobutyric acid, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, tryptophan, ornithine, lysine, histidine, and arginine. Nevertheless, these results suggest a possible relation and future research is warranted with increased amount of patients.
After enucleation, only one patient (6.7%) developed hepatic steatosis. This may be explained by the fact that significant less patients had recurrent disease after enucleation (1 of 25) and recurrence is the sole risk factor for NAFLD/NASH.
In contrast to the literature, only 6 of 33 PD patients (18%) from this cohort developed NAFLD/NASH. Most likely, an underestimation of patients with NAFLD/NASH is made in this study due to evaluation of imaging studies instead of the golden standard (liver biopsy). [15] [16] [17] [18] 20 If multiple imaging modalities were available, the imaging study with highest accuracy for detection of NAFLD/NASH was used; unenhanced CT, MRI, ultrasonography and contrast-enhanced CT, respectively.
Specificity for unenhanced CT for detection of NAFLD/NASH was 88.1-94.6%. 16 With MRI, hepatic steatosis can be accurately diagnosed both qualitatively and quantitatively. 17 Ultrasonography has overall 85% sensitivity and 94% specificity for hepatic steatosis. 18 Calculating blood-subtracted hepatic attenuation on contrast enhanced CT-images has increasing accuracy as the threshold level of hepatic steatosis increases. Sensitivity ranged from 62.1% to 87.5% in one study 19 and specificity from 86.2-100% in two studies. 19, 20 It is likely that the number of patients with postoperative new onset NAFLD/NASH after pancreatic resection was underestimated in this study, especially if the hepatic steatosis was of a mild degree, and because of the moderate to high sensitivity and specificity for all imaging studies.
Secondly, EPI after pancreatic surgery was investigated. In a study of Nakagawa et al 7 prevalence of postoperative EPI after PD was 65%. In our analysis, enucleations, total pancreatectomy and central and/or distal pancreatic pancreatectomy were also included.
As the extent of resection might play a role in the development of EPI, this possibly explains the difference in prevalence of EPI. This is supported by the fact that the majority of patients after enucleation (70.8%) did not develop EPI while the majority of patients after PD (76.9%) did develop EPI. 7 Multivariate analysis showed that PD is an independent predictor for the development of EPI. It is known that EPI is associated to remnant pancreatic volume and results in endocrine and exocrine insufficiency in case of total pancreatic resection. 25, 26 The same theory applies for distal pancreatic pancreatectomy after which the majority did not develop EPI ( To a lesser extent, this timeframe limitation due to our retrospective design also applies to all available imaging studies.
Although the majority of patients were followed in accordance with the guidelines, 27,28 a significant amount of data were missing, most likely due to loss to follow-up and death. 
| CONCLUSIONS
This is the first study that investigated development of EPI and NASH/ NAFLD in pNET patients after resection or enucleation (n = 112) with long follow-up period. Forty-nine percent of these patients developed EPI after pancreatic surgery, mostly after PD. New onset NAFLD/NASH after pNET resection is occasionally seen, especially in patients with recurrent disease. EPI was not a risk factor for development of NAFLD/NASH in our patient cohort. Due to suboptimal imaging studies to detect NAFLD/ NASH, likely there is an underestimation of NAFLD/NASH in this cohort and a clear explanation for current results was not found. Therefore, future (prospective) large studies are warranted to assess associations with hepatic steatosis after pancreatic surgery more accurately.
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